Navigation Links
Ortho Biotech Modifies Prescribing Information for PROCRIT(R) (Epoetin alfa) Label Reflects Recommendations from Recent FDA Advisory Committee Meetings
Date:11/8/2007

BRIDGEWATER, N.J., Nov. 8 /PRNewswire-FirstCall/ -- Ortho Biotech Products, L.P. today modified prescribing information for PROCRIT(R) (Epoetin alfa), following guidance from the U.S. Food and Drug Administration (FDA) to revise labeling for all drugs within the erythropoiesis-stimulating agent (ESA) class.

The modifications to the label are based on previously reported data and include recommendations from the May 10th FDA Oncologic Drugs Advisory Committee meeting, and the September 11th joint Cardiovascular and Renal Drugs Advisory Committee/Drug Safety & Risk Management Advisory Committee meeting.

"We remain confident in the safety and efficacy of PROCRIT when used according to its FDA-approved label," said Craig Tendler, M.D., Vice President, Medical Affairs, Oncology/ Nephrology, Ortho Biotech Products, L.P. "This label supports physicians' abilities to customize treatment to individual patients' needs by directing them to utilize the lowest dose needed to avoid transfusions and not to exceed an upper hemoglobin safety limit of 12 grams per deciliter (g/dL)."

Label Change Details

The modifications to the label include a hemoglobin target range of 10-12 g/dL of blood for chronic renal failure patients with anemia; a hemoglobin upper limit of 12 g/dL of blood for oncology patients with anemia due to chemotherapy; and additional data regarding shortened overall survival and/or time-to-tumor progression in clinical studies in patients with advanced breast, head and neck, lymphoid, and non-small cell lung malignancies when dosed to target a hemoglobin greater than or equal to 12 g/dL. In addition, recommendations have been added for managing chronic renal failure patients who respond poorly to ESA therapy.

The boxed warnings have been modified to now read:

WARNINGS: Increased Mortality, Serious Cardiovascular and Thromboembolic Events, and Tumor Progression

Renal failure: Patients experienced greater risks for death
'/>"/>

SOURCE Ortho Biotech
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Ortho Biotech Supports FDA Advisory Committees Recommendations on Use of ESAs in Chronic Renal Failure Patients
2. Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases
3. New Orthopedic Surgical Robotics Company Opens Its Doors; Files with the FDA for Clearance of Its Flagship Product
4. Innovative Neurotronics, a Subsidiary of Hanger Orthopedic Group, Earns the 2007 da Vinci Award for the WalkAide System
5. Bone-growing nanomaterial could improve orthopaedic implants
6. Advancements in Population Age and Technology Drive Future of Orthopedic Materials Market
7. Collagen Matrix, Inc. Launches OssiMend(TM) Bone Graft Matrix for Orthopedic and Spine Applications
8. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
9. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
10. ISI Increases West Coast Life Science and Biotech Support for Emerging Companies with Expansion in San Francisco and San Diego
11. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... UK (PRWEB) July 10, 2014 ... 21st Century Medicine Forum on ‘Commercialising Longevity Research’ ... and entrepreneurs to the London Bioscience Innovation Center ... Research Foundation and Aging Analytics Ltd. The meeting ... investment in translational research for age-related disease, as ...
(Date:7/10/2014)... 2014 Unraveling life’s mysteries can intrigue, ... Archer Family purchased a DNA test to ... up with a lifetime of memories, sharing, and closeness. ... members’ DNA genuinely brought the family closer together. ... into genetic history and prior to taking the ...
(Date:7/10/2014)... Montreal, QC (PRWEB) July 10, 2014 ... comfort and convenience. This rejuvenating device now comes with a ... that develops over time. , The new cup is thinner ... This design works to target rough, thin and uneven surfaces ... original firm cup for a stimulating treatment on areas such ...
(Date:7/10/2014)... 2014 On July 9 Prime ... presented Russia,s first national "Industry" ... Company is developing a unique project called MabNext ... a number of innovative drugs based on monoclonal antibodies ... took place at the International Exhibition "Innoprom 2014" in ...
Breaking Biology Technology:DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2
... Aug. 14 Transgenomic, Inc. (the,"Company") (OTC Bulletin Board: ... 30, 2007. The Company,s financial results are,presented in the ... Company reported a net profit of $0.2 million or ... compared to a net loss of $0.4 million or,$0.01 ...
... Genetics, Inc.,(Nasdaq: RGDX ), today reported financial ... "The second quarter of 2007 was very ... public offering in June," said,Kathleen Danenberg, President and ... the recent developments that have since been announced. ...
... Summertime equals fun for a lot of,folks. ... (IBS), typical,summer fare could also mean aggravating their ... for IBS," has more on,what people with IBS ... IBS from,ruining their celebrations. Listen to this ...
Cached Biology Technology:Transgenomic, Inc. Reports Second Quarter 2007 Results 2Transgenomic, Inc. Reports Second Quarter 2007 Results 3Transgenomic, Inc. Reports Second Quarter 2007 Results 4Transgenomic, Inc. Reports Second Quarter 2007 Results 5Transgenomic, Inc. Reports Second Quarter 2007 Results 6Transgenomic, Inc. Reports Second Quarter 2007 Results 7Transgenomic, Inc. Reports Second Quarter 2007 Results 8Response Genetics Reports Second Quarter 2007 Financial Results 2Response Genetics Reports Second Quarter 2007 Financial Results 3Response Genetics Reports Second Quarter 2007 Financial Results 4Response Genetics Reports Second Quarter 2007 Financial Results 5Response Genetics Reports Second Quarter 2007 Financial Results 6Response Genetics Reports Second Quarter 2007 Financial Results 7Response Genetics Reports Second Quarter 2007 Financial Results 8
(Date:7/10/2014)... Florida , July 1, 2014 ... pave way for convenience and improved security: NXT-ID, Inc. (OTCBB: ... (NASDAQ: GOOG ), Apple Inc. (NASDAQ: ... MasterCard Corporation (NYSE: MA) NXT-ID, Inc., (OTCQB: NXTD) a ... pleased to announce that the second series of 30 second ...
(Date:7/10/2014)... 2014 It is a great honor for ... of the world-renowned Thoracic and Cardiovascular surgeon, Mark E ... Dr. Ginsburg, with over 34 years of experience, is ... Good Samaritan Regional Medical Center. Dr. Ginsburg has been ... and is considered an expert in the implantation of ...
(Date:7/10/2014)... -- According to the new market research ... Material (Optical Prism, Pizeoelectric, Capacitive, and Adhesives), Application (Mobile ... Finance), and Geography - Global Trends & Forecasts to ... Sensors Market is projected to cross $14.35 Billion by ... 2014 to 2020. Browse more than 78 ...
Breaking Biology News(10 mins):Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 2Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 3Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 4Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 5Avery Biomedical Devices, Inc. announces the appointment of Mark E Ginsburg, M.D. to its Board of Directors 2Fingerprint Sensors Market worth $14.35 Billion by 2020 2Fingerprint Sensors Market worth $14.35 Billion by 2020 3
... Researchers at Burnham Institute for Medical Research at ... (a chain of amino acids) that specifically recognizes and ... was also shown to deliver diagnostic particles and medicines ... dramatically enhance both cancer detection and treatment. The work ...
... Mass. December 7, 2009 Biogen Idec (NASDAQ: ... fumarate) achieved key milestones in clinical trials for multiple ... the last patient was enrolled in the CONFIRM trial, ... evaluate the efficacy and safety of BG-12 as a ...
... Researchers from Yale University and Mirna Therapeutics, Inc., reversed ... occurring tumor suppressor microRNA. The study reveals that a ... role in cancer treatment, and provides hope for future patients ... cancers. "This is the first time anybody has shown a ...
Cached Biology News:Delivering medicine directly into a tumor 2Biogen Idec's oral compound BG-12 achieves development milestones in MS and RA 2
... anti-phospho-IRS1 (Tyr896) ... to amino acid region encompassing ... phospho-IRS1 (Tyr896). ... Quality Assurance: ...
Goat polyclonal to PPP2R5D Immunogen: Peptide with sequence KRAEEFLTASQEAL, from C Terminus of the protein sequence according to NP_006236...
...
Monoclonal Mouse Anti-Human Cytokeratin 16 (48 kD)...
Biology Products: